Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Tesamorelin Alternatives 2026 Best: Compound Comparison

| Compound | Mechanism | Dosing Frequency | Half-Life | Peak GH Elevation | Unique Advantage | Limitation ||—|—|—|—|—|—|| Tesamorelin | GHRH analog (receptor agonist) | Daily subcutaneous | 26–38 minutes | 4–6× baseline | FDA-approved for lipodystrophy; most c

This comparison does not assign a generated winner or score.

  • | Compound | Mechanism | Dosing Frequency | Half-Life | Peak GH Elevation | Unique Advantage | Limitation ||—|—|—|—|—|—|| Tesamorelin | GHRH analog (receptor agonist) | Daily subcutaneous | 26–38 minutes | 4–6× baseline | FDA-approved for lipodystrophy; most clinical data | Daily injections; short half-life || CJC-1295/Ipamorelin | GHRH analog + ghrelin agonist stack | 1× weekly (CJC) + 2× daily (Ipa) | 6–8 days (CJC); 2 hours (Ipa) | 5–8× baseline (pulsatile) | Physiological pulsatility; reduced injection frequency | Requires combination dosing; cold-chain storage || MK-677 (Ibutamoren) | Non-peptide ghrelin mimetic | Once daily oral | 24 hours | 2–3× baseline (sustained) | Oral bioavailability; no injections; no tachyphylaxis | Increased appetite; transient water retention || Hexarelin | Ghrelin receptor agonist (high potency) | Daily subcutaneous (short-term) | 1.5–2 hours | 10–15× baseline (acute) | Highest peak GH response; rapid onset | Receptor desensitization after 4 weeks; not